Fischer Laurent — SEC insider filings
SEC reporting owner CIK 1379344. 37 insider filings on record with FilingPulse; latest filed 2026-10-26.
Transaction summary — filings shown
Covers all 37 filings on record, filed 2020-08-19 to 2026-10-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 8 legs across 6 filings — 204,991 shares, $925,293 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 91,447 shares, $94,426 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 73.
- Largest priced transaction: purchase of 117,614 shares @ $4.31 ($506,916) in Adverum Biotechnologies, Inc., filed 2025-12-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Adverum Biotechnologies, Inc. (ADVM) | CEO, PRESIDENT AND DIRECTOR, Director | 20 | 8 legs · 204,991 sh · $925,293 | 3 legs · 91,447 sh · $94,426 | 44 |
| Mirum Pharmaceuticals, Inc. (MIRM) | Director | 7 | — | — | 11 |
| CTI BIOPHARMA CORP (CTIC) | Director | 4 | — | — | 10 |
| AtaiBeckley Inc. (ATAI) | Director | 2 | — | — | 4 |
| ATAI Life Sciences N.V. (ATAI) | Director | 2 | — | — | 2 |
| Lycia Therapeutics, Inc. (LYCA) | Director | 2 | — | — | 2 |
Insider filings — Fischer Laurent
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-26 | 4 | Lycia Therapeutics, Inc. (LYCA) | Grant/award (A): 13,307 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-10-22 | 3 | Lycia Therapeutics, Inc. (LYCA) | Holdings only — no transactions reported | EDGAR |
| 2026-09-11 | 4 | AtaiBeckley Inc. (ATAI) | Disposition to issuer (D): 206,000 (derivative) · Disposition to issuer (D): 103,000 (derivative) · Disposition to issuer (D): 121,968 (derivative) | EDGAR |
| 2026-06-17 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 3,772 (derivative) @ $0 · Grant/award (A): 1,980 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | AtaiBeckley Inc. (ATAI) | Grant/award (A): 121,968 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 3,977 · Option exercise (M): 3,977 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Option exercise (M): 150,000 @ $4.20 · Code (U): 351,513 · Code (U): 25,000 · Grant/award (A): 500,000 @ $0 · Code (U): 522,666 · Disposition to issuer (D): 93,000 (derivative) · +10 more | EDGAR |
| 2025-12-08 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 11,085 @ $4.24 · Purchase (P): 117,614 @ $4.31 | EDGAR |
| 2025-06-27 | 4 | ATAI Life Sciences N.V. (ATAI) | Grant/award (A): 103,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Disposition to issuer (D): 120,000 (derivative) @ $0 · Grant/award (A): 120,000 (derivative) @ $0 · Disposition to issuer (D): 68,000 (derivative) @ $0 · Grant/award (A): 68,000 (derivative) @ $0 · Disposition to issuer (D): 45,499 (derivative) @ $0 · Grant/award (A): 45,499 (derivative) @ $0 · +10 more | EDGAR |
| 2025-06-02 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 6,268 (derivative) @ $0 · Grant/award (A): 3,977 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Sale (S): 9,126 @ $2 | EDGAR |
| 2025-02-27 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 25,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2024-08-06 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | ATAI Life Sciences N.V. (ATAI) | Grant/award (A): 206,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 8,779 (derivative) @ $0 · Grant/award (A): 5,703 (derivative) @ $0 | EDGAR |
| 2024-03-12 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 315,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 1,104,200 (derivative) @ $0 | EDGAR |
| 2023-06-26 | 4 | CTI BIOPHARMA CORP (CTIC) | Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 126,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · +1 more | EDGAR |
| 2023-06-14 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-04-07 | 4 | CTI BIOPHARMA CORP (CTIC) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2023-03-17 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Sale (S): 41,239 @ $0.78 | EDGAR |
| 2023-03-03 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 930,000 (derivative) @ $0 | EDGAR |
| 2022-09-21 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Sale (S): 41,082 @ $1.07 | EDGAR |
| 2022-09-16 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 675,022 (derivative) @ $0 · Grant/award (A): 584,978 (derivative) @ $0 | EDGAR |
| 2022-06-06 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2022-04-22 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 25,000 @ $1.11 | EDGAR |
| 2022-03-17 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 630,000 (derivative) @ $0 | EDGAR |
| 2022-03-11 | 4 | CTI BIOPHARMA CORP (CTIC) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2021-12-10 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 10,677 @ $1.79 · Purchase (P): 14,323 @ $1.85 | EDGAR |
| 2021-08-10 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 680,000 @ $0 · Grant/award (A): 455,000 (derivative) @ $0 | EDGAR |
| 2021-06-08 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2021-03-24 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 10,000 @ $9.88 | EDGAR |
| 2021-03-12 | 4 | CTI BIOPHARMA CORP (CTIC) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2021-02-18 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 680,000 (derivative) @ $0 | EDGAR |
| 2021-01-19 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 8,600 @ $11.53 | EDGAR |
| 2020-08-19 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 7,692 @ $13 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1379344 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs